1
Kabanov Alexander V, Karas Michael, Bronitch Tatiana K, Dexter Robin: Pesticidal aggregates. Innovaform Technologies, Kabanov Alexander V, Karas Michael, Bronitch Tatiana K, Dexter Robin, FAIR Paul A, June 26, 2008: WO/2008/076807 (3 worldwide citation)

In one aspect, this invention relates to a substantially water-insoluble pesticidal aggregate produced from a mixture comprising: (a) a polymer having at least three similarly charged electrostatic moieties; (b) an amphiphilic surfactant having at least one electrostatically charged moiety of opposi ...


2
Kabanov Alexander V, Bronitch Tatiana K, Karas Michael: Pesticide delivery system. Innovaform Technologies, Kabanov Alexander V, Bronitch Tatiana K, Karas Michael, POSORSKE Laurence H, July 19, 2007: WO/2007/081965 (2 worldwide citation)

An improved pesticide delivery system is disclosed. The system is based on a microblend comprising (a) an amphiphilic compound containing at least one hydrophilic group and at least one hydrophobic group and (b) a pesticide. Compositions based on the microblend and methods of using the compositions ...


3
Kabanov Alexander V, Bronitch Tatiana K, Karas Michael, Frank Bruce L: Pesticide delivery system. Innovaform Technologies, Kabanov Alexander V, Bronitch Tatiana K, Karas Michael, Frank Bruce L, BENNER Dwight M, July 19, 2007: WO/2007/081961 (2 worldwide citation)

An improved pesticide delivery system is disclosed. The system is based on a microblend comprising (a) an amphophilic compound containing at least one hydrophilic group and at least one hydrophobic group and (b) a second compound. Compositions based on the microblend and methods of using the composi ...


4

5

6
Kabanov Alexander V, Lemieux Pierre M, Vinogradov Sergey V, Alakhov Valery Y: Polynucleotide compositions for intramuscular and intradermal administration. Supratek Pharma, Kabanov Alexander V, October 10, 2001: EP1140015-A1

The present invention relates to compositions of polynucleotides, such as viruses, RNA, DNA, or derivatives thereof comprising polynucleotides and block copolymers of alkylethers. The invention also relates to methods of treating animals comprising intramuscular and intradermal administration of the ...


7
Kabanov Alexander V, Alakhov Valery Yu, Sveshnikov Peter G, Severin Eugenii S: Compositions comprising an anticancer agent and a polyether block copolymer. Supratek Pharma, Kabanov Alexander V, May 14, 2003: EP1310244-A2

Novel pharmaceutical compositions comprising a chemotherapeutic agent and a polyether block copolymer, and method of treatment using the compositions.


8
Kabanov Alexander V, Alakhov Valery Y: Improvements in polymer compositions for chemotherapy and methods of treatment using the same. Supratek Pharma, Kabanov Alexander V, Alakhov Valery Y, September 8, 1999: EP0939640-A1

Improved antineoplastic compositions comprising an antineoplastic agent combined with a pluronic and a water-soluble non-toxic homopolymer resulting in a decrease of toxicity and/or an increase in anti-cancer activity, and methods of treatment using such formulations.


9
Alakhov Vallery Yu, Kabanov Alexander V, Sveshnikov Peter G, Severin Eugenii S: Composition dagents antineoplasiques, incorporee dans des micelles, Composition of antineoplastic agents incorporated in micelles. Alakhov Vallery Yu, Kabanov Alexander V, Sveshnikov Peter G, Severin Eugenii S, Supratek Pharma, DEETH WILLIAMS WALL, April 28, 1994: CA2125500

Compositions of anti-neoplastic agents incorporate the agent in micelles of at least one block copolymer of poly(oxyethy-lene)-poly(oxypropylene) in which the ratio of (oxypropylene) blocks to the (oxyethylene) blocks is from about 0.25 to about 1-5and the micelles have an average diameter of from a ...


10
Kabanov Alexander V, Lemieux Pierre, Guerin Nadia, Alakhov Valery: Compositions of non-ionic block copolymers to treat autoimmune, proliferative, and inflammatory diseases and methods of use thereof. Supratek Pharma, Kabanov Alexander V, February 5, 2003: EP1280537-A2

Compositions comprising non-ionic block copolymers are useful for the treatment of autoimmune, inflammatory and proliferative diseases and for reducing graft/implantation rejection. The present invention also relates to methods of treating animals having various autoimmune, inflammatory and prolifer ...